☆ 4.1 Article

A review of the state of cervical cancer: updates from prevention to recurrent disease

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Public, Environmental & Occupational Health

Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative

Deependra Singh et al.

Summary: Tracking progress and providing evidence are essential for countries to achieve the WHO's goal of eliminating cervical cancer. This study assessed global inequalities in cervical cancer incidence and mortality based on the GLOBOCAN 2020 estimates, considering geographical and socioeconomic factors.

LANCET GLOBAL HEALTH (2023)

添加到收藏夹

Article Oncology

Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Charles A. Leath et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

Linda R. Mileshkin et al.

Summary: This study aimed to determine the effects of adjuvant chemotherapy after chemoradiotherapy on survival. The results showed that adjuvant chemotherapy did not improve overall survival in patients with locally advanced cervical cancer, and it increased short-term toxicity.

LANCET ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

David M. O'Malley et al.

Summary: This phase II trial evaluated the efficacy of dual treatment with balstilimab and zalifrelimab in patients with recurrent and/or metastatic cervical cancer. The results showed promising and durable clinical activity, with favorable tolerability, in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Survival with Cemiplimab in Recurrent Cervical Cancer

K. S. Tewari et al.

Summary: Patients with recurrent cervical cancer after first-line platinum-containing chemotherapy showed significantly longer overall survival and progression-free survival when treated with Cemiplimab compared to single-agent chemotherapy. Overall, there was a higher objective response rate and lower incidence of grade 3 or higher adverse events in the Cemiplimab group.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge

J. Hoes et al.

Summary: Licensed HPV vaccines are highly effective in inducing high levels of neutralizing antibodies, but the correlation of protection against HPV is lacking and evidence for long-term antibody persistence is limited. The World Health Organization recommends immunization of young girls to eliminate cervical cancer, highlighting the need for long-lasting protection.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

添加到收藏夹

Article Oncology

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

Domenica Lorusso et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Fertility-Sparing and Less Radical Surgery for Cervical Cancer

Samantha H. Batman et al.

Summary: This review aims to evaluate the feasibility of fertility-sparing less radical surgery for patients with early-stage cervical cancer. Research findings indicate that the risk of parametrial involvement is less than 1% in carefully selected patients. Additionally, data from the recent ConCerv trial suggests that conservative surgery is a safe and feasible option for women with early-stage low-risk cervical cancer. Neoadjuvant chemotherapy is also being assessed as a way to extend fertility-sparing treatment to a larger group of women.

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Article Obstetrics & Gynecology

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Xiaohua Wu et al.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Proportions and incidence of locally advanced cervical cancer: a global systematic literature review

Bradley J. Monk et al.

Summary: This systematic literature review reveals global differences in the proportions of locally advanced cervical cancer, with regional variances and disparities according to patient race and age identified.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman et al.

Summary: This study evaluated the efficacy and safety of tisotumab vedotin in women with recurrent or metastatic cervical cancer. The drug showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in this patient population. Tisotumab vedotin could represent a new treatment option for women with recurrent or metastatic cervical cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

Richard Pötter et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

David M. O'Malley et al.

Summary: This study evaluated the safety and antitumor activity of the anti-PD-1 antibody balstilimab in patients with previously-treated, recurrent/metastatic cervical cancer. Balstilimab demonstrated meaningful clinical activity, with responses seen in both PD-L1 positive and negative tumors, as well as in cervical adenocarcinoma. The most common grade 3 or higher treatment-related adverse events were immune-mediated enterocolitis and diarrhea.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer

Kathleen M. Schmeler et al.

Summary: The ConCerv Trial aimed to evaluate the feasibility of conservative surgery in women with early-stage, low-risk cervical cancer. The results showed that select patients meeting specific criteria may be offered conservative surgery.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

N. Colombo et al.

Summary: Adding pembrolizumab to chemotherapy significantly improves progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer when compared to placebo. Anemia and neutropenia are the most common grade 3 to 5 adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Surveillance of Vaccination Coverage Among Adult Populations - United States, 2018

Peng-Jun Lu et al.

Summary: The translation highlights that many adults are at risk for illness and death from vaccine-preventable diseases. Despite the longstanding recommendations for vaccination, the coverage among U.S. adults remains low. The data indicate that substantial improvement in adult vaccination uptake is needed to reduce the burden of vaccine-preventable diseases.

MMWR SURVEILLANCE SUMMARIES (2021)

添加到收藏夹

Review Obstetrics & Gynecology

Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach

Alexander Melamed et al.

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2020)

添加到收藏夹

Article Oncology

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Alessandro D. Santin et al.

GYNECOLOGIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study

Shitanshu Uppal et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study

Jyoti Mayadev et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

HPV Vaccination and the Risk of Invasive Cervical Cancer

Jiayao Lei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Obstetrics & Gynecology

2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Rebecca B. Perkins et al.

JOURNAL OF LOWER GENITAL TRACT DISEASE (2020)

添加到收藏夹

Article Oncology

SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study

Fabrice R. Lecuru et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)

添加到收藏夹

Article Oncology

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Melanie Drolet et al.

LANCET (2019)

添加到收藏夹

Article Oncology

LBA62Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

R W Naumann et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

Pedro T. Ramirez et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer

Alexander Melamed et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Oncology

Bilateral Negative Sentinel Nodes Accurately Predict Absence of Lymph Node Metastasis in Early Cervical Cancer: Results of the SENTICOL Study

Fabrice Lecuru et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Long-term assessment of bladder and bowel dysfunction after radical hysterectomy

Rebecca A. Brooks et al.

GYNECOLOGIC ONCOLOGY (2009)

添加到收藏夹

Article Oncology

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

Bradley J. Monk et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.